Clinical Research Directory

Key Inclusion Criteria: * All: written informed consent; able to follow procedures, follow-up and contraception rules. * Part 1: healthy adults; BMI 18 to below 32 kg/m²; weight above 50 kg; suitable injection sites; able to complete confinement and blood sampling. * Part 2: Atopic Dermatitis for at least 12 months with inadequate response to topical prescription therapy (or such therapy unsuitable); BMI 17.5 to below 35 kg/m²; weight above 50 and below 120 kg; stable emollient use for at least 7 days without substantial improvement; washouts completed. * Cohort 1- participants not exposed to dupilumab (eligible for systemic therapy): EASI at least 16, vIGA-AD at least 3, body surface area at least 10%, weekly peak itch score at least 4. * Cohort 2- (dupilumab inadequate responder): at least 16 weeks of prior dupilumab; EASI at least 12, vIGA-AD at least 2, body surface area at least 5%, weekly peak itch score at least 3. Key Exclusion Criteria: * Clinically significant illness, infection, or laboratory or ECG abnormality; tuberculosis, helminth, HIV, hepatitis B or C (protocol exceptions apply). * Exclusionary malignancy or lymphoproliferative disorder; hypersensitivity; injection intolerance. * Recent prohibited treatments, investigational agents or live vaccines; pregnancy, breastfeeding or planned pregnancy; alcohol or drug misuse. * Part 2: interfering skin disease or active skin infection; systemic JAK inhibitor exposure over one month or non-response.